Showing 4 ideas for tag "failure"
(@ginawei) kudos icon +

AoU Research Priorities Use Cases

Develop more accurate and clinically relevant sub-classification/phenotyping of heart failure

Heart failure (HF), though relatively common in U.S. adults, can be thought of as a syndrome with many subtypes that require different treatments. All of Us provides a rich platform on which to collect more data (e.g., novel biomarkers and imaging studies) on HF patients. This, coupled with AoU’s existing rich genomics, behavioral, and clinical data, can be analyzed to refine the phenotyping and sub-classification of... more »

Voting

9 votes
Ideate
(@sachdevv) kudos icon +

AoU Research Priorities Use Cases

Using mobile technologies to empower heart failure patients to self-monitor and participate in disease management

Management of heart failure involves attention to salt/fluid intake, control of blood pressure, and daily weight monitoring. Physical activity has been shown to reduce hospitalizations in patients with reduced cardiac function and it may also play a role in diastolic heart failure. Recording data on home-measured parameters and linking them to cardiac outcomes will provide information on optimal methods for use of mobile... more »

Voting

10 votes
Ideate
(@ginawei) kudos icon +

AoU Research Priorities Use Cases

Identify and create a cohort of heart failure patients within All of Us to enable discovery and clinical research

Prevalence of heart failure (HF) in U.S. has risen to ~6.1 million among those ≥20 years of age. AoU provides a rich platform to identify HF patients through EHR (including clinical laboratory and imaging reports) and claims data. Ability to follow and collect data prospectively in the patients, including ancillary studies of more surveys and imaging/biomarker collections, could advance discovery science and address... more »

Voting

9 votes
Ideate
(@wye000) kudos icon +

AoU Research Priorities Use Cases

What is the long-term comparative effectiveness of empagliflozin in a heterogeneous population with type 2 diabetes?

Empaglifozin, a highly selective sodium-glucose cotransport 2 (SGLT2) inhibitor, has been shown to significantly reduce major adverse cardiovascular (CV) events and hospitalization for heart failure in patients with type 2 diabetes (T2DM) and established CV disease. The generalizability of this finding to lower risk population is unknown. We propose to compare cardiovascular outcomes in a more heterogeneous population... more »

Voting

3 votes
Ideate